New hepatitis C antiviral treatments eliminate the virus Doyle, Joseph S et al. The Lancet , Volume 0 , Issue 0 , Published: 06 July 2017, doi.org/10.1016/S0140-6736(17)31817-2 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)3…

Weder für Jugendliche noch für Erwachsene lässt sich aus den unvollständig übermittelten Daten ein Zusatznutzen ableiten. Die postulierte bessere Verträglichkeit ist nicht belegt. (Institut für Qualität und Wi…

USA. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. National Academies of Sciences, Engineering, and Medicine. 2017. Washington, DC: The National Academies Press. doi.org/10.17226/24731. https://www.nap.edu/cata…

Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. Eckhardt B, Winkelstein ER, Shu MA, Carden MR, McKnight C, Des Jarlais DC, et al. (2017) PLoS ONE 12(5): e0177341. doi…

Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. Elsherif O, Bannan C, Keating S, McKiernan S, Bergin C, Norr…

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conwa…